REAXA

• 21100 - Manufacture of basic pharmaceutical products

Reaxa was formed in 2005 as a joint venture between Avecia Pharmaceuticals and Steve Ley, Professor of Organic Chemistry at Cambridge University and was spun off at the time Avecia was acquired by Nicholas Piramal. Reaxa was last acquired by the S. Amit Group in 2011... Based on award-winning encapsulated catalyst technology (EnCat™), Reaxa has developed patented technology on encapsulation for precious metal catalysts such as Palladium, Platinum and base metals like Nickel and other metals. The products are designed to reduce metal contamination within manufacturing process streams which has the benefit of making processes both greener and more efficient. Reaxa's technology allows metal contamination to be minimised at source by encapsulating metals into a polyurea matrix... Reaxa™ has pioneered the approach to catalyst immobilisation using polymer encapsulation to help address the issues surrounding metal contamination.

Also known as: REAXA LIMITED

Registration numbers: 04884654 (CH)

Primary location: Edge United Kingdom